Potential antileukemia effect and structural analyses of SRPK inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl) isonicotinamide (SRPIN340)

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Siqueira, Raoni Pais ^a   Barbosa, Éverton De Almeida Alves ^a   Polêto, Marcelo Depólo ^a   Righetto, Germanna Lima ^b   Seraphim, Thiago Vargas ^c   Salgado, Rafael Locatelli ^a   Ferreira, Joana Gasperazzo ^a   De Andrade Barros, Marcus Vinícius ^a   De Oliveira, Leandro Licursi ^a   Laranjeira, Angelo Brunelli Albertoni ^d   Almeida, Márcia Rogéria ^a   Júnior, Abelardo Silva ^a   Fietto, Juliana Lopes Rangel ^a   Kobarg, Jörg ^e   De Oliveira, Eduardo Basílio ^a   Teixeira, Robson Ricardo ^a   Borges, Júlio César ^c   Yunes, Jose Andrés ^d   Bressan, Gustavo Costa ^a  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d CENTRO INFANTIL BOLDRINI   (Brazil)

^e BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N [2 (PIPERIDIN 1 YL) 5 (TRIFLUOROMETHYL)PHENYL]ISONICOTINAMIDE; PROTEIN KINASE INHIBITOR; SERINE ARGININE RICH PROTEIN; SERINE ARGININE RICH PROTEIN KINASE 1; SERINE ARGININE RICH PROTEIN KINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; SRPIN340; SRPK1 PROTEIN, HUMAN; SRPK2 PROTEIN, HUMAN;

ANTILEUKEMIA EFFECT; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; FAS GENE; FLUORESCENCE ANALYSIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOID CELL LINE; MAP2K1 GENE; MAP2K2 GENE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MYELOID LEUKEMIA CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STRUCTURE ANALYSIS; VEGF GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL CULTURE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HELA CELL LINE; HL-60 CELL LINE; JURKAT CELL LINE; K-562 CELL LINE; LEUKEMIA; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROFLUOROMETRY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION, LEUKEMIC; HELA CELLS; HL-60 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; NIACINAMIDE; PIPERIDINES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, FLUORESCENCE;

EID: 84941985106     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134882     Document Type: Article

References (56)

1. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008; 456: 470-476. doi: 10.1038/nature07509 PMID: 18978772
2. Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011; 18: 67-76. doi: 10. 1016/j.chembiol.2010.11.009 PMID: 21276940
3. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008; 8: 880-887. doi: 10.1038/nrc2505 PMID: 18923433
4. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol. 2010; 220: 152-163. doi: 10.1002/path. 2649 PMID: 19918805
5. Bourgeois CF, Lejeune F, Stevenin J. Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA. Prog Nucleic Acid Res Mol Biol. 2004; 78: 37-88. PMID: 15210328
6. Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009; 136: 701-718. doi: 10.1016/j.cell.2009.02.009 PMID: 19239890
7. Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 2009; 417: 15-27. doi: 10.1042/BJ20081501 PMID: 19061484
8. House AE, Lynch KW. Regulation of alternative splicing: more than just the ABCs. J Biol Chem. 2008; 283: 1217-1221. PMID: 18024429
9. Cho S, Hoang A, Chakrabarti S, Huynh N, Huang DB, Ghosh G. The SRSF1 linker induces semi-conservative ESE binding by cooperating with the RRMs. Nucleic Acids Res. 2011; 39: 9413-9421. doi: 10.1093/nar/gkr663 PMID: 21852328
10. Giannakouros T, Nikolakaki E, Mylonis I, Georgatsou E. Serine-arginine protein kinases: a small protein kinase family with a large cellular presence. FEBS J. 2011; 278: 570-586. doi: 10.1111/j.1742-4658.2010.07987.x PMID: 21205200
11. Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev. 2009; 23: 482-495. doi: 10.1101/gad.1752109 PMID: 19240134
12. Zhou Z, Fu XD. Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma. 2013; 122: 191-207. doi: 10.1007/s00412-013-0407-z PMID: 23525660
13. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010; 20: 87-90. doi: 10.1016/j.gde.2009.11.002 PMID: 20006486
14. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28: 1075-1083. doi: 10.1200/JCO.2009.25.3641 PMID: 20085938
15. Jang SW, Yang SJ, Ehlen A, Dong S, Khoury H, Chen J, et al. Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1. Cancer Res. 2008; 68: 4559-4570. doi: 10.1158/0008-5472.CAN-08-0021 PMID: 18559500
16. Aubol BE, Plocinik RM, Hagopian JC, Ma CT, McGlone ML, Bandyopadhyay R, et al. Partitioning RS domain phosphorylation in an SR protein through the CLK and SRPK protein kinases. J Mol Biol. 2013; 425: 2894-2909. doi: 10.1016/j.jmb.2013.05.013 PMID: 23707382
17. Wang P, Zhou Z, Hu A, Ponte de Albuquerque C, Zhou Y, Hong L, et al. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell. 2014; 54: 378-391. doi: 10.1016/j.molcel.2014.03.007 PMID: 24703948
18. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006; 66: 3819-3827. PMID: 16585209
19. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007; 67: 2072-2080. PMID: 17332336
20. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S, et al. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS One. 2012; 7: e46539. doi: 10.1371/journal.pone.0046539 PMID: 23071587
21. Wu Q, Chang Y, Zhang L, Zhang Y, Tian T, Feng G, et al. SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemosensitivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions. J Cancer. 2013; 4: 727-735. doi: 10.7150/jca.7576 PMID: 24312143
22. Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014; 111: 477-485. doi: 10.1038/bjc.2014.342 PMID: 25010863
23. Salesse S, Dylla SJ, Verfaillie CM. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia. 2004; 18: 727-733. PMID: 14961028
24. Hishizawa M, Imada K, Sakai T, Ueda M, Hori T, Uchiyama T. Serological identification of adult T-cell leukaemia-associated antigens. Br J Haematol. 2005; 130: 382-390. PMID: 16042687
25. Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A. 2006; 103: 11329-11333. PMID: 16840555
26. Hagiwara M, Fukuhara T, Suzuki M, Hosoya T. Method for Controlling Protein Phosphorilation, and Antiviral Agents Whose Active Ingredients Comprise Agents that Control SR Protein Activity. United States Patent. 2009; US7569536 B2.
27. Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother. 2010; 54: 3179-3186. doi: 10.1128/AAC.00113-10 PMID: 20498328
28. Anwar A, Hosoya T, Leong KM, Onogi H, Okuno Y, Hiramatsu T, et al. The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly. PLoS One. 2011; 6: e23246. doi: 10.1371/journal.pone.0023246 PMID: 21858043
29. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem. 2010; 285: 5532-5540. doi: 10.1074/jbc. M109.074930 PMID: 19906640
30. Gammons MV, Dick AD, Harper SJ, Bates DO. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013; 54: 5797-5806. doi: 10.1167/iovs.13-11634 PMID: 23761094
31. Dong Z, Noda K, Kanda A, Fukuhara J, Ando R, Murata M, et al. Specific inhibition of serine/argininerich protein kinase attenuates choroidal neovascularization. Mol Vis. 2013; 19: 536-543. PMID: 23559848
32. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011; 20: 768-780. doi: 10.1016/j.ccr.2011.10.016 PMID: 22172722
33. Carneiro FR, Silva TC, Alves AC, Haline-Vaz T, Gozzo FC, Zanchin NI. Spectroscopic characterization of the tumor antigen NY-REN-21 and identification of heterodimer formation with SCAND1. Biochem Biophys Res Commun. 2006; 343: 260-268. PMID: 16540086
34. Silva KP, Seraphim TV, Borges JC. Structural and functional studies of Leishmania braziliensis Hsp90. Biochim Biophys Acta. 2013; 1834: 351-361. doi: 10.1016/j.bbapap.2012.08.004 PMID: 22910377
35. Breneman CM, Wiberg KB. Determining atom-centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis. Journal of Computational Chemistry. 1990; 11: 361-373.
36. Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JH, et al. General Atomic and Molecular Electronic Structure System. J Comput Chem. 1993; 14: 1347-1363.
37. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004; 60: 1355-1363. PMID: 15272157
38. Ngo JC, Giang K, Chakrabarti S, Ma CT, Huynh N, Hagopian JC, et al. A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1. Mol Cell. 2008; 29: 563-576. doi: 10.1016/j.molcel.2007.12.017 PMID: 18342604
39. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and Auto-DockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30: 2785-2791. doi: 10.1002/jcc.21256 PMID: 19399780
40. Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. J Comput Chem. 2007; 28: 1145-1152. PMID: 17274016
41. Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013; 29: 845-854. doi: 10.1093/bioinformatics/btt055 PMID: 23407358
42. Oostenbrink C, Villa A, Mark AE, van Gunsteren WF. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem. 2004; 25: 1656-1676. PMID: 15264259
43. Gammons MV, Fedorov O, Ivison D, Du C, Clark T, Hopkins C, et al. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci. 2013; 54: 6052-6062. doi: 10.1167/iovs.13-12422 PMID: 23887803
44. Clery A, Sinha R, Anczukow O, Corrionero A, Moursy A, Daubner GM, et al. Isolated pseudo-RNA-recognition motifs of SR proteins can regulate splicing using a noncanonical mode of RNA recognition. Proc Natl Acad Sci U S A. 2013; 110: E2802-2811. doi: 10.1073/pnas.1303445110 PMID: 23836656
45. Kim H, Choi K, Kang H, Lee SY, Chi SW, Lee MS, et al. Identification of a novel function of CX-4945 as a splicing regulator. PLoS One. 2014; 9: e94978. doi: 10.1371/journal.pone.0094978 PMID: 24743259
46. Zahler AM, Lane WS, Stolk JA, Roth MB. SR proteins: a conserved family of pre-mRNA splicing factors. Genes Dev. 1992; 6: 837-847. PMID: 1577277
47. Wang HY, Lin W, Dyck JA, Yeakley JM, Songyang Z, Cantley LC, et al. SRPK2: a differentially expressed SR protein-specific kinase involved in mediating the interaction and localization of premRNA splicing factors in mammalian cells. J Cell Biol. 1998; 140: 737-750. PMID: 9472028
48. Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, et al. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro. PLoS One. 2012; 7: e51030. doi: 10.1371/journal.pone.0051030 PMID: 23236423
49. Naro C, Sette C. Phosphorylation-mediated regulation of alternative splicing in cancer. Int J Cell Biol. 2013; 2013: 151839. doi: 10.1155/2013/151839 PMID: 24069033
50. Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A. 2006; 103: 11329-11333. PMID: 16840555
51. Hong Y, Jang SW, Ye K. The N-terminal fragment from caspase-cleaved serine/arginine protein-specific kinase2 (SRPK2) translocates into the nucleus and promotes apoptosis. J Biol Chem. 2011; 286: 777-786. doi: 10.1074/jbc.M110.193441 PMID: 21056976
52. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010; 10: 130-137. doi: 10.1038/nrc2787 PMID: 20094047
53. Aubol BE, Nolen B, Shaffer J, Ghosh G, Adams JA. Novel destabilization of nucleotide binding by the gamma phosphate of ATP in the yeast SR protein kinase Sky1p. Biochemistry. 2003; 42: 12813-12820. PMID: 14596595
54. Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, et al. Serinearginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. 2014; doi: 10.1038/onc.2014.360
55. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000; 25: 169-193. PMID: 11013345
56. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques. 2005; 39: 75-85. PMID: 16060372